Hansa Medical to present IdeS at the World Orphan Drug Congress USA, April 24 in Washington D.C.

The presentation focusing on Hansa Medical’s lead drug-candidate IdeS’ capacity for desensitization prior to kidney transplantation is scheduled for 3:15 pm on April 24.

The World Orphan Drug Congress USA will be held on April 23-25 at the Grand Hyatt Washington, Washington D.C. For more information about the event please visit: www.terrapinn.com/2014/world-orphan-drug-congress-usa.

The company presentation’s emphasize will be on its lead drug-candidate IdeS, IdeS’ recent clinical Phase I results and IdeS’ forthcoming Phase II studies in 2014.

For further information, please contact:
Hansa Medical AB
Emanuel Björne, CEO Hansa Medical AB (publ)
Mobile: 46 707 17 54 77
E-mail: emanuel.bjorne@hansamedical.com
www.hansamedical.com

Hansa Medical pursues clinical development and commercialization of innovative pharmaceuticals and diagnostic methods for the benefit of patients with serious and rare inflammatory diseases. The portfolio includes a marketed diagnostic product, a drug candidate in clinical development, and a preclinical research project. Major shareholders are Bo Håkansson via Farstorps Gård AB, and Nexttobe AB. Hansa Medical is listed on NASDAQ OMX First North (HMED) and Remium Nordic AB is the company’s Certified Adviser.

About Us

Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Other projects include HBP (a market introduced diagnostic marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's share (HMED) is listed on Nasdaq First North in Stockholm with Remium Nordic AB as Certified Adviser.

Subscribe

Documents & Links